Retrospective Analysis of Arginase 1 Deficiency Progression in Adults over 5 years at a Single Metabolic Centre

Overview

Journal JIMD Rep

Publisher Wiley

Date 2024 Nov 8

PMID 39512428

Authors

Reena Sharma

John Bassett

Karolina M Stepien

Andrew Oldham

Ana Jovanovic

Alison Woodall

Diane Green

Affiliations

Soon will be listed here.

Abstract

Background: The clinical presentation of ARG1-D is characterised by elevated arginine levels leading to neurological and mobility impairments. Information about long-term outcomes in adults is lacking, which prompted us to undertake a retrospective observational study.

Methods: We extracted ARG1-D patient data spanning a 5-year period from electronic health records. Ethical approval was not required for the study. Informed consent was obtained.

Results: We identified nine ARG1-D patients from consanguineous backgrounds. Age of symptom onset ranged from infancy to age 7 years, age of diagnosis from infancy to 20 years. Patients had paraparesis or altered gait of varying degree and had experienced early ARG1-D onset. Over 5 years, mobility declined in six (6/9, 67%) patients. Three patients (3/9, 33%) were fully dependent and hoisted. Two (2/9, 22%) reached adulthood before experiencing hyperammonaemia, another one (1/9, 11%) first experienced hyperammonaemia at age 15 years. One patient (1/9, 11%) started on ammonia scavenger therapy in adulthood, one (1/9, 11%) required a second scavenger to be added to their treatment regimen. Two patients (2/9, 22%) had gastrostomy tubes inserted for nutrition and supplements at age 9 years and 15 years. Six patients (6/9, 67%) had raised levels of ALT; of these, four (4/9, 44%) also had elevated AFP. Heterogeneity of ARG1-D symptoms was evident, suggesting complex genetic and environmental interactions.

Conclusion: ARG1-D presents significant lifelong challenges with deteriorating mobility and more frequent metabolic crises. Current management strategies are insufficient for preventing progression, highlighting the need for innovative treatments like enzyme replacement and gene therapy.

References

Chandra S, Christopher R, Ramanujam C, Harikrishna G . Hyperargininemia Experiences over Last 7 Years from a Tertiary Care Center. J Pediatr Neurosci. 2019; 14(1):2-6. PMC: 6601119. DOI: 10.4103/jpn.JPN_1_19. View

Cui B, Wei L, Sun L, Qu W, Zeng Z, Liu Y . The effect of liver transplantation for argininemia-the largest experiences in a single center. Transl Pediatr. 2022; 11(4):495-504. PMC: 9085954. DOI: 10.21037/tp-21-576. View

Amayreh W, Meyer U, Das A . Treatment of arginase deficiency revisited: guanidinoacetate as a therapeutic target and biomarker for therapeutic monitoring. Dev Med Child Neurol. 2014; 56(10):1021-4. DOI: 10.1111/dmcn.12488. View

Marescau B, De Deyn P, Qureshi I, De Broe M, Antonozzi I, Cederbaum S . The pathobiochemistry of uremia and hyperargininemia further demonstrates a metabolic relationship between urea and guanidinosuccinic acid. Metabolism. 1992; 41(9):1021-4. DOI: 10.1016/0026-0495(92)90131-s. View

Russo R, Gasperini S, Bubb G, Neuman L, Sloan L, Diaz G . Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial. EClinicalMedicine. 2024; 68:102405. PMC: 10825663. DOI: 10.1016/j.eclinm.2023.102405. View

Diaz G, Bechter M, Cederbaum S . The role and control of arginine levels in arginase 1 deficiency. J Inherit Metab Dis. 2022; 46(1):3-14. PMC: 10091968. DOI: 10.1002/jimd.12564. View

Asrani K, Cheng L, Cheng C, Subramanian R . Arginase I mRNA therapy - a novel approach to rescue arginase 1 enzyme deficiency. RNA Biol. 2018; 15(7):914-922. PMC: 6161738. DOI: 10.1080/15476286.2018.1475178. View

Carvalho D, Brum J, Speck-Martins C, Ventura F, Navarro M, Coelho K . Clinical features and neurologic progression of hyperargininemia. Pediatr Neurol. 2012; 46(6):369-74. DOI: 10.1016/j.pediatrneurol.2012.03.016. View

Burrage L, Madan S, Li X, Ali S, Mohammad M, Stroup B . Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency. JCI Insight. 2020; 5(4). PMC: 7101134. DOI: 10.1172/jci.insight.132342. View

10.

Catsburg C, Anderson S, Upadhyaya N, Bechter M . Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence. Orphanet J Rare Dis. 2022; 17(1):94. PMC: 8889696. DOI: 10.1186/s13023-022-02226-8. View

11.

Koo M, Lipshutz G, Cederbaum S, Lassman C . Biopsy-proven Hepatocellular Carcinoma in a 53-year-old Woman With Arginase Deficiency. Pediatr Dev Pathol. 2017; 20(6):517-521. DOI: 10.1177/1093526617697058. View

12.

Stepien K, Geberhiwot T, Hendriksz C, Treacy E . Challenges in diagnosing and managing adult patients with urea cycle disorders. J Inherit Metab Dis. 2019; 42(6):1136-1146. DOI: 10.1002/jimd.12096. View

13.

Ibrahim M, Gold J, Woodall A, Yilmaz B, Gissen P, Stepien K . Diagnostic and Management Issues in Patients with Late-Onset Ornithine Transcarbamylase Deficiency. Children (Basel). 2023; 10(8). PMC: 10453542. DOI: 10.3390/children10081368. View

14.

Diaz G, Schulze A, McNutt M, Leao-Teles E, Merritt 2nd J, Enns G . Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2020; 44(4):847-856. PMC: 8359196. DOI: 10.1002/jimd.12343. View

15.

Diez-Fernandez C, Rufenacht V, Gemperle C, Fingerhut R, Haberle J . Mutations and common variants in the human arginase 1 (ARG1) gene: Impact on patients, diagnostics, and protein structure considerations. Hum Mutat. 2018; 39(8):1029-1050. DOI: 10.1002/humu.23545. View

16.

Hertecant J, Al-Gazali L, Karuvantevida N, Ali B . A novel mutation in ARG1 gene is responsible for arginase deficiency in an Asian family. Saudi Med J. 2009; 30(12):1601-3. View

17.

Huemer M, Carvalho D, Brum J, Unal O, Coskun T, Weisfeld-Adams J . Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency. J Inherit Metab Dis. 2016; 39(3):331-340. DOI: 10.1007/s10545-016-9928-y. View

18.

Munder M . Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol. 2009; 158(3):638-51. PMC: 2765586. DOI: 10.1111/j.1476-5381.2009.00291.x. View

19.

Bin Sawad A, Jackimiec J, Bechter M, Trucillo A, Lindsley K, Bhagat A . Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review. Mol Genet Metab. 2022; 137(1-2):153-163. DOI: 10.1016/j.ymgme.2022.08.005. View

20.

Haberle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M . Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019; 42(6):1192-1230. DOI: 10.1002/jimd.12100. View